68Ga-PSMA PET/CT in Initial Diagnosis and Bone Metastasis Evaluation in Saudi Patients with High-Grade Prostate Cancer

ORIGINAL ARTICLE
Sahar Mansour, Meshael Al-Khalaf, Sarah Al-Hantoshi, Mead Al-Mutairi, Fatima Al-Asqah, Nouf Al-Subaie, Sadeem Al-Qarni, Futun Suwaylim, Rawan F. Alkhodiri, Ola Faden, Abdulrahman Albatly

 
For citation: Mansour S, Al-Khalaf M, Al-Hantoshi S, Al-Mutairi M, Al-Asqah F, Al-Subaie N, Al-Qarni S, Suwaylim F, Alkhodiri RF, Faden O, Albatly A. 68Ga-PSMA PET/CT in Initial Diagnosis and Bone Metastasis Evaluation in Saudi Patients with HighGrade Prostate Cancer. International Journal of Biomedicine. 2024;14(1):72-76. doi:10.21103/Article14(1)_OA10
 
Originally published March 1, 2024

Abstract: 

We present the first study performed in Saudi Arabia to evaluate 68Ga-PSMA PET/CT in prostate cancer (PCa) initial diagnosis and its added value in bone metastases (BM) diagnosis in such patients. Twenty-six male patients underwent prostate histopathological examination and all imaging studies (68Ga-PSMA PET/CT and CT); all of them were confirmed with high-grade PCa. Patients' mean PSA levels and Gleason score were 5.12±1.12 and 7.0±0.9, respectively. 68Ga-PSMA PET/CT (20/26; sensitivity of 76.9%) was superior to traditional CT (18/26; sensitivity of 69.2%) in PCa detection. There was a non-significant association (P=0.206) between patients' age and BM. Based on bone scintigraphy (BS), in patients without BM (n=16), 68Ga-PSMA PET/CT detected metastasis-suspicious lesions in six patients (37.5%) and negative results in ten patients (62.5%). 68Ga-PSMA PET/CT showed no false-negative cases among patients with confirmed BM using BS.
In conclusion, 68Ga-PSMA PET/CT performed well in PCa initial diagnosis in Saudi male patients with high-grade tumors. 68Ga-PSMA PET/CT also accurately detected BM in all PCa patients with confirmed BM by BS. Larger prospective studies are urgently required to compare 68Ga-PSMA PET/CT diagnostic performance with other standard modalities in PCa and BM diagnosis.

Keywords: 
prostate cancer • 68Ga-PSMA PET/CT • diagnosis • bone metastasis • sensitivity
References: 
  1. Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Front Public Health. 2022 Feb 16;10:811044. doi: 10.3389/fpubh.2022.811044. PMID: 35252092; PMCID: PMC8888523.
  2. Patasius A, Smailyte G. Re: MaryBeth B. Culp, Isabelle Soerjomataram, Jason A. Efstathiou, Freddie Bray, Ahmedin Jemal. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol 2020;77:38-52. Eur Urol. 2020 May;77(5):e132. doi: 10.1016/j.eururo.2019.11.030. Epub 2019 Dec 13. PMID: 31843337.
  3. Alasker A, Alghafees M, Chaudhri EN, Al Qurashi AA, Abdul Rab S, Sabbah BN, Musalli Z, Alyami A. An unusually high prevalence of isolated prostatic ductal adenocarcinoma among Saudi patients: A registry-based study. Urol Ann. 2023 Jul-Sep;15(3):320-324. doi: 10.4103/ua.ua_46_23. Epub 2023 Jul 17. PMID: 37664104; PMCID: PMC10471815.
  4. Satapathy S, Singh H, Kumar R, Mittal BR. Diagnostic Accuracy of 68Ga-PSMA PET/CT for Initial Detection in Patients With Suspected Prostate Cancer: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2021 Mar;216(3):599-607. doi: 10.2214/AJR.20.23912. Epub 2021 Jan 21. PMID: 32755196.
  5. Descotes JL. Diagnosis of prostate cancer. Asian J Urol. 2019 Apr;6(2):129-136. doi: 10.1016/j.ajur.2018.11.007. Epub 2019 Feb 14. PMID: 31061798; PMCID: PMC6488713.
  6. Prcic A, Begic E, Hiros M. Usefulness of Total PSA Value in Prostate Diseases Diagnosis. Acta Inform Med. 2016 Jun;24(3):156-61. doi: 10.5455/aim.2016.24.156-161. Epub 2016 Jun 4. PMID: 27482127; PMCID: PMC4949038.
  7. Lomas DJ, Ahmed HU. All change in the prostate cancer diagnostic pathway. Nat Rev Clin Oncol. 2020 Jun;17(6):372-381. doi: 10.1038/s41571-020-0332-z. Epub 2020 Feb 28. PMID: 32112055.
  8. Stabile A, Giganti F, Rosenkrantz AB, Taneja SS, Villeirs G, Gill IS, Allen C, Emberton M, Moore CM, Kasivisvanathan V. Multiparametric MRI for prostate cancer diagnosis: current status and future directions. Nat Rev Urol. 2020 Jan;17(1):41-61. doi: 10.1038/s41585-019-0212-4. Epub 2019 Jul 17. PMID: 31316185.
  9. Zhen L, Liu X, Yegang C, Yongjiao Y, Yawei X, Jiaqi K, Xianhao W, Yuxuan S, Rui H, Wei Z, Ningjing O. Accuracy of multiparametric magnetic resonance imaging for diagnosing prostate Cancer: a systematic review and meta-analysis. BMC Cancer. 2019 Dec 23;19(1):1244. doi: 10.1186/s12885-019-6434-2. PMID: 31870327; PMCID: PMC6929472.
  10. Richenberg J, Løgager V, Panebianco V, Rouviere O, Villeirs G, Schoots IG. The primacy of multiparametric MRI in men with suspected prostate cancer. Eur Radiol. 2019 Dec;29(12):6940-6952. doi: 10.1007/s00330-019-06166-z. Epub 2019 Jun 6. PMID: 31172275; PMCID: PMC6828624.
  11. Palot Manzil FF, Kaur H, Szabados L. Gallium-68 Prostate-Specific Membrane Antigen Positron Emission Tomography: A Practical Guide for Radiologists and Clinicians. Cureus. 2022 Mar 7;14(3):e22917. doi: 10.7759/cureus.22917. PMID: 35399427; PMCID: PMC8986511.
  12. Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT. Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. PMID: 30843003.
  13. Van den Wyngaert T, Strobel K, Kampen WU, Kuwert T, van der Bruggen W, Mohan HK, Gnanasegaran G, Delgado-Bolton R, Weber WA, Beheshti M, Langsteger W, Giammarile F, Mottaghy FM, Paycha F; EANM Bone & Joint Committee and the Oncology Committee. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1723-38. doi: 10.1007/s00259-016-3415-4. Epub 2016 Jun 4. PMID: 27262701; PMCID: PMC4932135.
  14. Zacho HD, Manresa JAB, Aleksyniene R, Ejlersen JA, Fledelius J, Bertelsen H, Petersen LJ. Three-minute SPECT/CT is sufficient for the assessment of bone metastasis as add-on to planar bone scintigraphy: prospective head-to-head comparison to 11-min SPECT/CT. EJNMMI Res. 2017 Dec;7(1):1. doi: 10.1186/s13550-016-0252-1. Epub 2017 Jan 5. PMID: 28058659; PMCID: PMC5215994.
  15. Zhao G, Ji B. Head-To-Head Comparison of 68Ga-PSMA-11 PET/CT and 99mTc-MDP Bone Scintigraphy for the Detection of Bone Metastases in Patients With Prostate Cancer: A Meta-Analysis. AJR Am J Roentgenol. 2022 Sep;219(3):386-395. doi: 10.2214/AJR.21.27323. Epub 2022 Apr 20. Erratum in: AJR Am J Roentgenol. 2022 Sep;219(3):529. PMID: 35441529.
  16. Haran C, McBean R, Parsons R, Wong D. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre. J Med Imaging Radiat Oncol. 2019 Aug;63(4):495-499. doi: 10.1111/1754-9485.12885. Epub 2019 Apr 11. PMID: 30972933.
  17. Lopci E, Lughezzani G, Castello A, Saita A, Colombo P, Hurle R, Peschechera R, Benetti A, Zandegiacomo S, Pasini L, Casale P, Pietro D, Bevilacqua G, Balzarini L, Buffi NM, Guazzoni G, Lazzeri M. Prospective Evaluation of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Primary Prostate Cancer Diagnosis. Eur Urol Focus. 2021 Jul;7(4):764-771. doi: 10.1016/j.euf.2020.03.004. Epub 2020 Apr 17. PMID: 32312701.
  18. Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, Eade T, Nguyen QA, Thompson BD, Cusick T, McCarthy M, Tang C, Ho B, Stricker PD, Scott AM. The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. J Nucl Med. 2018 Jan;59(1):82-88. doi: 10.2967/jnumed.117.197160. Epub 2017 Jun 23. PMID: 28646014.
  19. Sachpekidis C, Bäumer P, Kopka K, Hadaschik BA, Hohenfellner M, Kopp-Schneider A, Haberkorn U, Dimitrakopoulou-Strauss A. 68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer. Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):904-912. doi: 10.1007/s00259-018-3936-0. Epub 2018 Jan 23. PMID: 29362859.
  20. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al, EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25. PMID: 27568654.
  21. Fonager RF, Zacho HD, Langkilde NC, Petersen LJ. (18)F-fluoride positron emission tomography/computed tomography and bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer patients: study protocol for a multicentre, diagnostic test accuracy study. BMC Cancer. 2016 Jan 11;16:10. doi: 10.1186/s12885-016-2047-1. PMID: 26753880; PMCID: PMC4709935.
  22. Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, Tamaki N, Schwaiger M, Maurer T, Eiber M. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2114-2121. doi: 10.1007/s00259-016-3435-0. Epub 2016 Jun 12. PMID: 27290607.
  23. Thomas L, Balmus C, Ahmadzadehfar H, Essler M, Strunk H, Bundschuh RAJP. Assessment of bone metastases in patients with prostate cancer—a comparison between 99mTc-bone-scintigraphy and [68Ga] Ga-PSMA PET/CT. Pharmaceuticals (Basel). 2017;31:68.

Download Article
Received December 12, 2023.
Accepted January 5, 2024.
©2024 International Medical Research and Development Corporation.